CASI Pharmaceuticals Inc CASIF
News
Trading Information
- Previous Close Price
- $0.11
- Day Range
- $0.11–0.11
- 52-Week Range
- $0.05–2.13
- Bid/Ask
- $0.11 / $0.17
- Shares Outstanding
- 20.56M
- Market Cap
- $2.16M
- Volume/Avg
- 2,000 / 2,408
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.11
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 214
Competitors
Valuation
|
Metric
|
CASIF
|
PFE
|
|---|---|---|
Price/Earnings (Normalized) | — | 9.31 |
Price/Book Value | — | 1.90 |
Price/Sales | 0.11 | 2.55 |
Price/Cash Flow | — | 10.56 |
Price/Earnings
CASIF
PFE
Financial Strength
|
Metric
|
CASIF
|
PFE
|
|---|---|---|
Quick Ratio | 0.11 | 0.85 |
Current Ratio | 0.15 | 1.27 |
Interest Coverage | −22.75 | 2.36 |
Quick Ratio
CASIF
PFE
Profitability
|
Metric
|
CASIF
|
PFE
|
|---|---|---|
Return on Assets (Normalized) | −171.67% | 8.46% |
Return on Equity (Normalized) | — | 19.70% |
Return on Invested Capital (Normalized) | — | 12.66% |
Return on Assets
CASIF
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SH#XF@ | LOCK|s$@Lw | $129B | |||
| Moderna Inc
MRNA
| LOCK|fx!>NqX | LOCK|^G | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$Mr$bl | LOCK|W!KCb | $79B | |||
| argenx SE ADR
ARGX
| LOCK|Z#X^>#! | LOCK|G<D | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<&khc! | LOCK|L<$ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PS@$M@ | LOCK|Rym!V | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^lK@B&k? | LOCK|dHxt | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|BwyX%X | LOCK|B! | $24B | |||
| Incyte Corp
INCY
| LOCK|KcDDN& | LOCK|tR% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&LgdN@ | LOCK|!y | $14B |
United States